Clinical Research
corporate_fare

Sparingvision

Address
5-7 Avenue Percier

Sponsor Overview

assignment
2
sponsored trials
science
0
molecules
location_city
3
research centres
public
3
countries
person_search
4
investigators

Specializations

Inherited retinal dystrophies

Sparingvision focuses on clinical research in severe inherited eye disorders affecting the retina, with particular attention to rod-cone dystrophy and related forms of progressive visual loss. Its studies center on genetic eye disease and the preservation of retinal function in advanced disease.

  • End-stage rod-cone dystrophy
  • Advanced retinal degeneration
  • Visual impairment

The sponsor’s research activity is concentrated in ophthalmology, particularly conditions where inherited defects lead to deterioration of photoreceptor function and loss of central and peripheral vision.

Gene therapy for retinal disease

The company funds clinical programs exploring gene therapy approaches for retinal disorders, including investigational treatments designed to address the underlying genetic basis of inherited retinal dystrophy. This area reflects a strong therapeutic interest in molecularly targeted intervention for blinding eye disease.

  • Retinal gene transfer
  • Ocular genetic medicine
  • Photoreceptor rescue

Research efforts are directed toward restoring or preserving retinal activity in patients with advanced rod-cone dystrophy and related degenerative conditions.

Intravitreal ophthalmic therapies

Sparingvision also supports development of intravitreal treatment strategies for retinal disorders, with interest in direct ocular delivery of novel biologic therapies. This therapeutic domain is closely linked to interventions aimed at the posterior segment of the eye.

  • Ocular delivery
  • Retinal administration
  • Vision-related outcomes

Its clinical portfolio is centered on diseases in which targeted eye-specific therapy is relevant to maintaining retinal structure and function.

Sponsored Trials

Trial Name Country Status
Evaluation of SPVN06 Gene Therapy Safety and Tolerability in Patients with Inherited Retinal Dystrophies, Specifically Rod Cone DystrophyFrance FranceNot Recruiting
Safety and Tolerability of Intravitreal SPVN20 Gene Therapy in End-Stage Rod-Cone Dystrophy with Dormant Foveal Cone PhotoreceptorsBelgium BelgiumFrance FranceIreland IrelandRecruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
0
Exclusive Molecules
out of 0 total (0% not shared with other sponsors)

This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
33%
Return partnership rate
1 of 3 sites collaborated multiple times

This sponsor has worked with 3 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Eye Diseases2 trials
    138 other sponsors

Partnered Research Centres

3 centres
location_city
assignment39
Quinze-Vingts National Ophthalmology Hospital
Address
28 Rue De Charenton, 75012 Paris
Learn morearrow_forward
location_city
assignment3
Royal Victoria Eye And Ear Hospital
Address
Adelaide Road, D02 XK51 Dublin
Learn morearrow_forward
location_city
assignment811
Universitair Ziekenhuis Gent
Address
Corneel Heymanslaan 10, 9000 Ghent
Learn morearrow_forward

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Sparingvision.

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.